An exciting Panel Discussion with some very eminent industry professionals from the telecom industry. The 3 key areas that we are going to discuss include:

The regulators perspective
Revenue sharing between content providers and regulators
What are the operators views and their views on the ecosystem evolving

Some of the very critical regulatory changes that have happened in the past which have impacted the mobile VAS industry are being discussed in the panel, with a major focus on security.
Location based services are very critical says the moderator.
We now have aspects of the various panelists …

Dr. Bakulesh Kumar, talks about Cancer as a disease and the drugs related. In US this is the only disease against which Fed Govt. has raised a war. There is a speacial provision for Cancer research and Clinical Trials. Every year they come out with a progress report which shows how the US is working against cancer as a disease.
This is a major problem in the US and hence worldwide, and hence we are talking about Phase III trials. Leaders worry that U.S is losing edge on cancer clinical trials. …

Dr. Akhilesh Sharma on Day two of the Clinical Trials Asia 2010 by Virtue Insight. We are going to discuss some very interesting pointers.

Primary research
Patient Demographics
Trial design options
Collaboratiosn – saleable aspects – stakeholders

Talking about the endpoints and the methodology Dr. Sharma says its important to look at the regulatory requirements and match the same with the vision of where we are looking at taking the development. You need to be very cautious while planning your studies. A whole lot of information analysis is important. we need to draw parallels from …

Talking about transformation of Clinical research with a focused Start-up Group! Why start-up group?

Managed by dedicated expert group
Well versed with rapidly evolving regulatory environment
Structured methodology of processing documents
Consistency with client requirements
Availability of monitoring resources for on-sites visits

We start with Regulatory Document preparation/ Review and Submission. Timelines and the quality of documents are gong to become more and more important. Its not a simple document, but its a document which we are using repetitively in all our trials all across the world.
Why can’t we have processes such as in the IT …

We keep on dreaming only. Where is the vision says one of the panelists, while comparing CRO’s in India and other parts of the world. IF there is no quality the Clinical Trial fails. We are still in the infant stage in terms of Clinical Trial.
We have a tremendous opportunity. The backbone of our clinical trial is the evidence of our medicine. We are all looking for accredited services. We must have a multi stakeholders which forms a consortium.
Talking about regulatory regime in India, interestingly the insight is many CROs …